Successful switch (tOPV to bOPV) in India: Tribute to a resilient health system.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
17 04 2019
Historique:
received: 26 07 2018
revised: 14 02 2019
accepted: 18 02 2019
pubmed: 19 3 2019
medline: 15 8 2020
entrez: 19 3 2019
Statut: ppublish

Résumé

In accordance with the end game strategies for polio eradication a synchronized switch plan from tOPV to bOPV was implemented globally in 2016. The National Committee for Polio Eradication (NCCPE) validated the switch activities in India. An expert group of 104 academics conducted field visits in 25 states and 2 Union territories for independent verification (after an initial round of verification by the National Polio Surveillance Project [NPSP]). The objectives were to validate withdrawal and disposal of tOPV by screening cold chain points in public and private sector health facilities in both rural and urban areas; additionally, availability of bOPV and IPV was also documented. 34 filled tOPV and 5 empty vials were detected inside cold chain equipment and 17 outside. The disposal mechanism was found to be reasonably adequate. The key strategies -- 'throttling' of vaccine supplies well ahead of the switch date while preventing stock outs at various immunization points, simultaneously working with the regulators to delicense the tOPV on the switch date and helping manufacturers to calibrate vaccine production according to national timelines, and strong and persistent advocacy with professional associations to align with national bOPV and IPV policy facilitated successful accomplishment of the switch process. Effective implementation of the switch strategy in India also bears testimony to the resilience of the health system operating under diverse and heterogeneous governance.

Identifiants

pubmed: 30879830
pii: S0264-410X(19)30243-9
doi: 10.1016/j.vaccine.2019.02.038
pii:
doi:

Substances chimiques

Poliovirus Vaccine, Inactivated 0
Poliovirus Vaccine, Oral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2394-2400

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Rajib Dasgupta (R)

National Certification Committee for Polio Eradication, New Delhi, India.

Shweta Sharma (S)

National Certification Committee for Polio Eradication Secretariat, New Delhi, India.

Nisha Sharma (N)

National Certification Committee for Polio Eradication Secretariat, New Delhi, India.

K Banerjee (K)

National Certification Committee for Polio Eradication, New Delhi, India.

E G P Haran (EGP)

National Certification Committee for Polio Eradication, New Delhi, India.

J P Muliyel (JP)

National Certification Committee for Polio Eradication, New Delhi, India.

Subhash Salunke (S)

National Certification Committee for Polio Eradication, New Delhi, India.

Muneer Ahmad Masoodi (MA)

National Certification Committee for Polio Eradication, New Delhi, India.

Pradeep Haldar (P)

Ministry of Health and Family Welfare, New Delhi, India.

Sunil Bahl (S)

SEARO WHO, New Delhi, India.

Pankaj Bhatnagar (P)

National Polio Surveillance Project, New Delhi, India.

Sudhir Joshi (S)

National Polio Surveillance Project, New Delhi, India.

Narendra K Arora (NK)

National Certification Committee for Polio Eradication, New Delhi, India. Electronic address: nkarora@inclentrust.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH